FindTrial
Sign In

ATG-022

DRUG3 trials

Sponsors

Antengene Biologics Limited

Conditions

Advanced Gastric or Gastroesophageal Junction AdenocarcinomaAdvanced/Metastatic Solid TumorsUnresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Phase 1

A Study of ATG-022 in Patients With Advanced/Metastatic Solid Tumors
RecruitingNCT05718895
Antengene Biologics LimitedAdvanced/Metastatic Solid Tumors
Start: 2023-03-27End: 2027-12-30Target: 156Updated: 2026-04-15
A Phase Ib/II Study of ATG-022 Plus Pembrolizumab With/Without Chemotherapy in Participants With Claudin (CLDN) 18.2-positive, HER2-negative, Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaUnresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
RecruitingNCT07327229
Antengene Biologics LimitedUnresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Start: 2026-02-27End: 2029-04-30Target: 132Updated: 2026-07-29

Phase 3

A Study of ATG-022 Compared With Investigator's Choice of Treatment in Claudin 18.2-Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Not yet recruitingNCT07795346
Antengene Biologics LimitedAdvanced Gastric or Gastroesophageal Junction Adenocarcinoma
Start: 2026-09-01End: 2029-12-31Target: 380Updated: 2026-08-31

Related Papers

Safety and preliminary efficacy of ATG-022 in patients with advanced/metastatic gastric cancer (CLINCH).
Journal of Clinical Oncology2025-01-272 citations
An open-label, multicenter, phase I study of ATG-022 in patients with advanced/metastatic solid tumors (CLINCH).
Journal of Clinical Oncology2024-06-011 citations